- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05970224
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage (BIRCH)
November 30, 2023 updated by: Bioxodes S.A.
A Phase IIa, Randomized, Open-label, Proof-of-Concept Study to Evaluate Safety, Tolerability and Efficacy of Ir-CPI in Patients With Spontaneous Intracerebral Haemorrhage
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
32
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Charlotte Corbisier
- Phone Number: +32 (0)472 21 01 20
- Email: charlotte.corbisier@bioxodes.com
Study Locations
-
-
-
Brussels, Belgium
- Recruiting
- UZ Brussel
-
Contact:
- Karen Vandaele
-
Brussels, Belgium
- Recruiting
- UCL St Luc
-
Contact:
- Ayhan Findik
-
Brussels, Belgium, 1070
- Recruiting
- HUB Erasme
-
Contact:
- Patrick Lamotte
-
-
East Flanders
-
Gent, East Flanders, Belgium, 9000
- Recruiting
- UZ Gent
-
Contact:
- Wendy Stoop
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgium
- Recruiting
- UZ Leuven
-
Contact:
- Annemie Devroye
-
-
Hainaut
-
Mons, Hainaut, Belgium, 7000
- Recruiting
- CHU Ambroise Pare
-
Contact:
- Virginie Vanderhaegen
-
-
West Flanders
-
Brugge, West Flanders, Belgium, 8000
- Recruiting
- AZ Sint-Jan
-
Contact:
- Heleen Couckuyt
-
Kortrijk, West Flanders, Belgium, 8500
- Recruiting
- Az Groeninge
-
Contact:
- Isabelle Vanpantghem
-
Oostende, West Flanders, Belgium, 8400
- Recruiting
- AZ Damiaan
-
Contact:
- Louise Vandenbroucke
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female patients aged ≥ 18 years.
- Written informed consent obtained before any study assessment. If the patient is not able to give the informed consent personally, consent by a legal representative as defined by local law and regulation is acceptable.
- First-ever, spontaneous, supratentorial intracerebral haemorrhage in cerebral cortex or deep brain structures (putamen, thalamus, caudate, and associated deep white matter tracts) with a volume ≥ 5 mL and ≤ 60 mL determined by non-contrast CT scan.
- Patients with Glasgow Coma Scale (GCS) best motor score no less than 5.
- Modified Rankin Scale (mRS) score 0-2 prior to ICH symptom onset.
Exclusion Criteria:
- History of personal or familial bleeding disorders; including prolonged or unusual bleeding.
- Known deficiency in factor XII (FXII) or haemophilia type A (FVII) or type B (FIX) or type C (FXI).
- Infratentorial (midbrain, pons, medulla, or cerebellum) ICH.
- Secondary ICH due to aneurysm, brain tumour, arteriovenous malformation, thrombocytopenia, coagulopathy, acute sepsis, traumatic brain injury (TBI), or disseminated intravascular coagulation (DIC).
- Planned neurosurgical hematoma evacuation or other urgent surgical intervention (i.e., surgical relief of increased intracranial pressure) on initial presentation.
- Planned anticoagulation reversal treatment.
- Patients with intraventricular haemorrhage (IVH) having a Graeb score of >3 on initial presentation. Patients must not have blood in the 4th ventricle and may only have blood in the 3rd ventricle in the absence of ventricular expansion. Trace or mild haemorrhage in either or both lateral ventricles is permitted. Patients with hydrocephalus determined radiologically on initial presentation are excluded regardless of Graeb score.
- Use of immunosuppressive or immune-modulating therapy at admission (e.g., steroids, methotrexate, monoclonal antibodies, etc).
- Patients with active systemic bacterial, viral or fungal infections.
- Women of childbearing potential.
- Have a body weight > 120 kg at screening.
- Severe renal impairment (eGFR < 30 mL/min/1.73 m2).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ir-CPI
Ir-CPI will be administered on top of standard of care
|
Participants receive a single intravenous dose of Ir-CPI during 48 hours
|
No Intervention: Standard care
Only standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of abnormalities in physical examination
Time Frame: 7 days post-randomization
|
A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, dermatological, neurological (including basic neurological testing for isocoria, light reflexes, gait and balance), musculoskeletal and lymphatic systems, in addition to head, eyes, ears, nose, throat, and neck.
|
7 days post-randomization
|
Change from baseline in HR interval
Time Frame: 7 days post-randomization
|
Measured by standard 12-lead ECG
|
7 days post-randomization
|
Change from baseline in PR interval
Time Frame: 7 days post-randomization
|
Measured by standard 12-lead ECG
|
7 days post-randomization
|
Change from baseline in QRS duration
Time Frame: 7 days post-randomization
|
Measured by standard 12-lead ECG
|
7 days post-randomization
|
Change from baseline in QRS axis
Time Frame: 7 days post-randomization
|
Measured by standard 12-lead ECG
|
7 days post-randomization
|
Change from baseline in QT interval
Time Frame: 7 days post-randomization
|
Measured by standard 12-lead ECG.
Two corrections of the QT interval will be investigated: Fridericia's correction (QTcF) and Bazett's correction (QTcB)
|
7 days post-randomization
|
Change from baseline in blood pressure
Time Frame: 7 days post-randomization
|
Blood pressure (systolic and diastolic) is measured using an automatic device
|
7 days post-randomization
|
Change from baseline in heart rate
Time Frame: 7 days post-randomization
|
Heart rate is measured using an automatic device
|
7 days post-randomization
|
Change from baseline in body temperature
Time Frame: 7 days post-randomization
|
Measurement of tympanic temperature
|
7 days post-randomization
|
Number of Participants with Adverse Events
Time Frame: 360 days post-randomization
|
360 days post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in perihematomal oedema (PHO) and haemorrhage volumes
Time Frame: 10 days post-randomization
|
CT scans will be acquired by volumetric CT acquisition with reconstructions in 3 planes, in order to assess hematoma volume and perihematomal volume.
Assessment of hematoma expansion will be performed by comparing follow-up CT scans with baseline CT.
|
10 days post-randomization
|
Measurement of the effect of Ir-CPI on the activated Partial Thromboplastin Time (aPTT)
Time Frame: 7 days post-randomization
|
Activated partial thromboplastin time (aPTT) will be used as a pharmacodynamic marker
|
7 days post-randomization
|
Measurement of the effect of Ir-CPI on the inhibition of Factor XI (FXI) and Factor XII (FXII) procoagulant activities
Time Frame: 7 days post-randomization
|
The inhibition of Factor XI (FXI) and Factor XII (FXII) procoagulant activities will be assessed to support the aPTT dynamics
|
7 days post-randomization
|
Change from baseline in Ir-CPI plasma concentrations
Time Frame: 7 days post-randomization
|
7 days post-randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2023
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
July 1, 2027
Study Registration Dates
First Submitted
July 24, 2023
First Submitted That Met QC Criteria
July 24, 2023
First Posted (Actual)
August 1, 2023
Study Record Updates
Last Update Posted (Actual)
December 1, 2023
Last Update Submitted That Met QC Criteria
November 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Clin_IrCPI_201
- 2022-500491-53-00 (Registry Identifier: CTIS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on Ir-CPI
-
Bioxodes S.A.Completed
-
Corvus Pharmaceuticals, Inc.Completed
-
Massachusetts General HospitalCrisis Prevention InstituteCompleted
-
Coordination Pharmaceuticals, Inc.Completed
-
Coordination Pharmaceuticals, Inc.Completed
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; MorphoSys AG; Swim Across America; Daniel...RecruitingMycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary SyndromeUnited States
-
Constellation PharmaceuticalsThe Leukemia and Lymphoma SocietyCompleted
-
University of Texas Southwestern Medical CenterWithdrawnPeripheral Nerve TumorsUnited States
-
Wake Forest University Health SciencesCompleted
-
Cornerstone PharmaceuticalsCompletedLymphoma | Metastatic Cancer | Advanced Cancer | Solid Tumors | Advanced MalignanciesUnited States, Canada